Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

NACDS Submits Comments to President’s Commission on Combating Drug Addiction and the Opioid Crisis
  • USA - English


News provided by

NACDS

Jul 10, 2017, 15:25 ET

Share this article

Share toX

Share this article

Share toX


Arlington, Va. (PRWEB) July 10, 2017 -- National Association of Chain Drug Stores (NACDS) President and CEO Steven C. Anderson, IOM, CAE, submitted official comments to the President’s Commission on Combating Drug Addiction and the Opioid Crisis, which is chaired by New Jersey Governor Chris Christie. President Donald Trump signed an Executive Order on March 29, 2017, establishing the Commission. The comments reflect NACDS’ long-standing and ongoing commitment to help address prescription drug abuse, addiction and proper access.

We believe that there are a variety of ways to help curb prescription drug diversion, and chain pharmacies actively work on many initiatives to reduce this problem.

Post this

Anderson described chain pharmacies’ “zero tolerance for prescription drug diversion” and extensive efforts to prevent it – including regulatory compliance, company-specific measures and collaboration with law enforcement and other authorities. He also noted challenges involved in pharmacists’ ethical duty to serve patients’ medical needs while meeting requirements of the Drug Enforcement Administration (DEA) to evaluate the legitimacy of the use of controlled substances.

Anderson wrote:

“The ongoing opioid abuse problem concerns both legal and illicit substances; that is, prescription opioids as well as heroin and illegal fentanyl analogs. NACDS and the chain pharmacy industry are committed to partnering with law enforcement agencies, policymakers, and others to work on viable strategies to prevent prescription drug diversion and abuse, including prescription opioids. One encouraging statistic is the decrease in the number of opioid prescriptions dispensed annually over the past few years. The number of opioid prescriptions dispensed at retail pharmacies declined almost 15% from 2013-2016 (Xponent, QuintilesIMS, 2017). Chain pharmacies engage daily in activities with the goal of preventing drug diversion and abuse. Since chain pharmacies operate in almost every community in the U.S., we support policies and initiatives to combat the prescription drug abuse problem nationwide. We believe that holistic approaches must be implemented at the federal level. We are pleased that we are helping to solve the opioid abuse problem.

“Pharmacists take their role in helping to ensure safe use of medications very seriously—but they cannot do it alone. We support a collaborative approach to curb prescription drug abuse and preserve patient access to their medically-necessary pain medications. We believe that there are a variety of ways to help curb prescription drug diversion, and chain pharmacies actively work on many initiatives to reduce this problem.”

Anderson also advised the Commission on opportunities to enhance existing strategies to curb opioid abuse, including in the following areas:
• Patient and Provider Education: “NACDS supports prescriber education initiatives. NACDS also supports education efforts targeted at the general public…We have encouraged collaboration among FDA [the Food and Drug Administration]; the Institute of Medicine (IOM), and other agencies and stakeholders to identify further opportunities and develop prescriber education tools for other controlled substances. Additionally, we have encouraged collaboration among ONDCP [the Office of National Drug Control Policy] and state boards of medicine to ensure enhanced training for prescribers on the legitimate use of controlled substances…We have encouraged FDA to expedite implementation of the one-document solution, as doing so could help to ensure that patients who are prescribed controlled substances better understand appropriate use of these medications.”
• Controlled Substance Prescription Drug Monitoring Programs (PDMP): “Unfortunately, there is great variability among state PDMPs…There exist no nationwide standards for the data that these programs collect, maintain, or provide; nor are there any nationwide standards for who may access the data among health care providers such as prescribers and pharmacists, health plans and Medicaid, or law enforcement officials; and there is no nationwide interconnectivity among the programs, which hinders regional surveillance of patients at risk and potential criminals. NACDS supports initiatives to establish a robust, national database with timely, reliable information and a standard set of requirements.”
• Role of Electronic Prescribing: “NACDS is supporting draft federal legislation that would require prescriptions for controlled substances in the Medicare Part D program to be issued electronically. In addition, NACDS recently developed model state legislative language to pursue mandatory electronic prescribing for all prescriptions…We urge that the Administration finalize the DEA interim final rule (IFR) that allows for the electronic prescribing of controlled substances. The current limitations in the IFR serve as barriers to more widespread adoption of electronic prescribing technologies. Finally, we urge CMS to move to the latest version of the National Council for Prescription Drug Programs (NCPDP) SCRIPT Standard so that prescribers and pharmacies may take full advantage of current electronic prescribing technologies.”
• Limiting Initial Fills of Controlled Substance Prescriptions: “Several states have enacted laws or rules to establish limits on the maximum day supply that prescribers can authorize on initial prescriptions for certain controlled substances. A growing number of states are considering legislation that would enact similar limits… Notably, there is variation across states with respect to the scope of these policies, especially concerning the pending legislative proposals…NACDS advocates for standardized policies that ease implementation challenges so that patient care is not adversely impacted. We believe that the Commission could serve as a forum to assist states with implementing standardized policies.”
• Promoting Access to Naloxone: “Pharmacists and pharmacies are primed to work in conjunction with other healthcare providers to increase access to naloxone for overdose prevention purposes…A number of states have employed various approaches to make it easier for pharmacists to provide naloxone to patients…Chain pharmacy supports state laws and policies…that eliminate administrative barriers to pharmacist-provided naloxone by authorizing pharmacists to provide naloxone without patient-specific prescriptions…Additionally, we support liability protections for all healthcare providers, including pharmacists, who prescribe and dispense naloxone in good faith.”
• Take-back and Disposal of Consumers’ Unused Medications: “NACDS supports the safe and effective disposal of unwanted consumer medications, including controlled substances, to stem the abuse of such drugs and to better protect the environment…We believe that policymakers who have decided to tackle the drug disposal issue should ensure that pharmacies are able to create programs that best serve the needs of their patients, as well as workable solutions for their store locations. Overall, patients should have a wide variety of options for how they can dispose of their unused medications. With more options, we can expect to have higher patient participation in prescription drug disposal programs…When policymakers consider proposals for drug disposal, we ask that they consider retail pharmacies’ support for broad drug disposal programs that allow pharmacies to facilitate at least one of a variety of DEA authorized options for drug disposal…Retail pharmacies support consumer education programs on drug disposal developed and funded by the government and/or pharmaceutical manufacturers…Ideally, such materials would focus on the dangers of misuse and the potential for addiction to prescription controlled substances, treatment resources available, and the proper way to dispose of unused prescription controlled substances…Finally, any legislative package adopting the policy proposals outlined above should also include a preemption provision. NACDS encourages the Commission to work with DEA to promote continued periodic take-back events hosted by DEA. We also encourage the Commission to pursue patient education programs as outlined above.”
• Collaborative Legislative Solutions: “NACDS and our members are focusing our energies on real, workable solutions that will address the problem of prescription drug abuse while also ensuring that legitimate patients are able to receive their prescription pain medications. In line with this goal, we supported the recently enacted 'Ensuring Patient Access and Effective Drug Enforcement Act' (P.L. 114-145). This legislation requires HHS [Department of Health and Human Services] to submit a report to Congress that identifies obstacles to legitimate patient access to controlled substances and outlines how collaboration among federal and state agencies and industry can benefit patients and prevent diversion and abuse of controlled substances…The report must be submitted to Congress no later than one year after the date of enactment. HHS has not met the one-year deadline for submitting this report to Congress.”
• Target Illegitimate Internet Drug Sellers: “NACDS believes that an important strategy to stop drug diversion and abuse is addressing the problem of illegitimate internet drug sellers. These illicit online drug sellers have websites that target U.S. consumers with ads to sell drugs often without any prescription required. They operate in clear violation of U.S. state and federal laws and regulations that protect public health and safety. They sell drugs to consumers without the safety precautions of a legitimate prescriber-patient relationship, a valid prescription, or a licensed U.S. pharmacy. We support targeting illegal internet drug sellers by enabling entities, such as domain name registrars that issue websites, financial entities that handle payment transactions, internet service providers that show the illegitimate websites on the internet, and common carriers that provide the mailing services, to stop illicit transactions at their point of interaction with these bad actors. NACDS serves on the Board of Directors of the Alliance for Safe Online Pharmacies (ASOP) to support their work to shut down illegal internet drug sellers.”
• Shutting Down Rogue Pain Clinics: “As the number of domestic-based rogue internet pharmacies has declined, there has been an increase in the number of rogue pain clinics. According to DEA, the practitioners in these clinics are responsible for the dispensing of millions of dosage units of oxycodone, a schedule II narcotic. NACDS supports the efforts of states that have enacted legislation to shut down these rogue clinics, such as the restriction of physicians’ ability to dispense oxycodone from pain clinics.”
Anderson’s complete comments include enhanced details related to each existing strategy and to each recommendation to the Commission.

Chris Krese, NACDS, http://www.nacds.org, +1 (703) 837-4650, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.